International Journal of Information Science and Computing
Citation: *IJISC*: **11**(01): 29-41, June 2024
DOI: 10.30954/2348-7437.1.2024.4

INFORMATION SCIENCE AND TECHNOLOGY FOUNDATION

REVIEW PAPER

The Role of Artificial Intelligence in Ovarian Cancer Diagnosis and Prognosis

Sanjukta Chakraborty

Department of Computer Science and Engineering, Seacom Skills University, Bolpur, Birbhum, West Bengal, India
Corresponding author: sanjukta.guddi@gmail.com

Received: 18 Mar., 2024 **Revised:** 28 May, 2024 **Accepted:** 06 June., 2024

ABSTRACT

Ovarian cancer, with its high fatality rate, continues to pose a major challenge in cancer treatment, primarily because it is often diagnosed at advanced stages and there are no dependable methods for early detection. Current diagnostic approaches, such as imaging and biomarker analysis, often time consuming to provide the necessary specificity and sensitivity, leading to delayed interventions. Artificial Intelligence (AI), utilizing advanced Machine Learning (ML) and Deep Learning (DL) techniques, is transforming the diagnosis and prognosis of ovarian cancer. This overview examines the significant impact of AI in boosting early detection, increasing diagnostic accuracy, and personalizing treatment approaches. AI-driven algorithms, especially Convolutional Neural Networks (CNNs), have demonstrated great potential in processing complex medical data, such as imaging, genomic information, and clinical records. In early detection, AI integrates biomarkers such as CA-125 levels with imaging findings to stratify patients into risk categories, minimizing false positives and negatives. In diagnostic imaging, AI enhances the interpretation of ultrasound, CT, and MRI scans by identifying subtle features that distinguish malignant from benign masses, significantly improving radiological accuracy. In addition to diagnosis, AI is crucial in forecasting patient outcomes by evaluating multi-dimensional data to determine tumor aggressiveness, recurrence risks, and treatment responses. This helps in creating personalized treatment strategies tailored to tumor genomics and individual patient profiles. Furthermore, AI-driven drug discovery speeds up the identification of new therapeutic agents, further enhancing precision oncology. However, despite its potential, AI faces challenges, including the need for high-quality datasets, transparency in algorithms, and addressing ethical issues like data privacy and bias. However, with continued technological advancements and interdisciplinary collaboration, AI has the potential to transform ovarian cancer management, ultimately improving survival rates and patient well-being. This abstract highlights the significance of AI as an essential resource in the fight against ovarian cancer.

Keywords: Ovarian Cancer, Early Detection, Artificial Intelligence, Machine Learning, Deep Learning, Personalized Treatment

How to cite this article: Chakraborty, S. (2024). The Role of Artificial Intelligence in Ovarian Cancer Diagnosis and Prognosis. *IJISC.,* **11**(01): 29-41.

Source of Support: None; **Conflict of Interest:** None

Ovarian cancer is one of the deadliest gynecological cancers, typically detected at later stages because early symptoms are non-specific, and effective screening methods are not available. This highlights the urgent need for innovative approaches to enhance early diagnosis and accurate prognosis, which could significantly improve treatment outcomes and survival rates. Artificial Intelligence (AI) holds significant promise in the field of ovarian cancer, thanks to its capacity to handle and analyze complex data. By utilizing AI technologies like machine learning (ML) and deep learning (DL), scientists and medical professionals are creating innovative approaches for detecting, classifying, and predicting outcomes of ovarian cancer. This introduction highlights the crucial role of AI in diagnosing and forecasting ovarian cancer, focusing on its impact on clinical decision-making and personalized treatment strategies.

1. The Challenge of Ovarian Cancer Diagnosis

Ovarian cancer remains a silent killer due to its subtle symptoms, which are often mistaken for benign conditions. Current diagnostic techniques, including imaging (ultrasound, CT, MRI) and biomarker analysis (e.g., CA-125) are time consuming. Consequently, most cases are detected at Stage III or IV, when therapeutic interventions are less effective. Traditional histopathological evaluation of tissue samples, while reliable, is time-intensive. AI has the potential to overcome these challenges by facilitating the integration and analysis of various data types, such as medical images, genomic information, and electronic health records (EHR). Machine learning techniques, especially those using neural networks, can detect intricate patterns and relationships within these datasets that might be overlooked by humans. For instance, convolutional neural networks (CNNs) are gaining popularity for improving the precision of interpreting radiological and pathological images[1].

2. AI in Early Detection and Screening

Early detection is critical for improving ovarian cancer survival rates. AI-powered tools are being employed to develop predictive models that integrate clinical data, imaging findings, and biomarkers to stratify patients into risk categories. These tools can help identify women who are at elevated risk of developing ovarian cancer, leading to the initiation of prompt diagnostic tests. One promising application is the use of AI algorithms to analyze biomarkers such as CA-125 levels alongside ultrasonographic findings. AI can improve the specificity of these tests by correlating biomarker fluctuations with imaging features, thus reducing false positives and negatives. Furthermore, advanced machine learning techniques can assist in screening high-risk populations by incorporating data from genetic testing, such as BRCA1 and BRCA2 mutations, into comprehensive risk assessment models.

3. Advancements in Diagnostic Imaging

AI's most profound impact in ovarian cancer diagnosis lies in imaging analysis. Traditional imaging techniques depend on radiologists' expertise to identify malignant lesions. AI-based systems, however, can rapidly process large volumes of imaging data, highlight suspicious regions, and provide quantitative assessments of tumor size, shape, and vascularity. Deep learning models, particularly CNNs, are revolutionizing the interpretation of ultrasound, MRI, and CT images. These models excel at detecting early-stage ovarian tumors by learning intricate features that distinguish malignant from benign masses.

For instance, AI-enhanced Doppler imaging can evaluate blood flow patterns in ovarian masses, aiding in malignancy determination.AI also supports radiomics, a field that extracts quantitative features from medical images to identify cancer phenotypes. By integrating radiomic data with clinical and genomic information, AI-driven tools provide a more comprehensive diagnostic framework, potentially transforming ovarian cancer management.

4. Role of AI in Prognosis and Treatment Planning

Beyond diagnosis, AI has a critical role in predicting patient outcomes and tailoring treatments. Prognostic models powered by machine learning analyze diverse datasets, including histopathological images, genomic alterations, and patient demographics, to predict survival rates, recurrence risks, and therapeutic responses. For example, AI algorithms can evaluate tumor microenvironment characteristics, such as immune cell infiltration and angiogenesis, to predict the aggressiveness of ovarian cancer. These insights guide oncologists in choosing optimal treatment strategies, such as surgery, chemotherapy, targeted therapy, or immunotherapy.

5. Personalized Medicine and AI

AI's capacity to handle multi-dimensional data facilitates the development of personalized treatment plans. By integrating genomic data, such as tumor mutation profiles and gene expression patterns, with clinical information, AI models can identify patient-specific therapeutic targets. This method supports precision oncology, allowing treatments to be customized based on the molecular characteristics of each patient's tumor. Furthermore, AI-powered drug discovery platforms are uncovering new therapeutic compounds for ovarian cancer. These platforms leverage deep learning to analyze chemical libraries and predict the efficacy of drug candidates, accelerating the development of targeted therapies[2].

6. Challenges and Ethical Considerations

Despite its potential, incorporating AI into ovarian cancer treatment presents several obstacles. High-quality, annotated datasets are crucial for developing effective AI models, but these datasets are often limited. Moreover, AI systems need to be validated across a variety of populations to ensure they are applicable to all groups and free from biases.

Ethical issues, including data privacy, transparency of algorithms, and accountability, also need to be carefully considered. Ensuring patient confidentiality while utilizing AI tools is paramount, as is providing clinicians and patients with clear explanations of AI-generated recommendations.

The use of AI in diagnosing and predicting ovarian cancer marks a transformative change in oncology. By facilitating earlier detection, boosting diagnostic precision, and supporting personalized treatment strategies, AI could greatly enhance patient outcomes. Continued progress in AI technologies, along with collaborative efforts between data scientists, medical professionals, and researchers, will help incorporate these innovations into everyday clinical care. As the field advances, it will be essential to tackle issues related to data quality, algorithmic bias, and ethical concerns to fully leverage AI's potential in the fight against ovarian cancer.

MATERIALS AND METHODS

Artificial Intelligence (AI) has become a game-changing tool in healthcare, providing solutions to the challenges of diagnosing and managing complex conditions like ovarian cancer.

This literature review examines the progress, uses, and impact of AI in diagnosing and predicting ovarian cancer, with an emphasis on machine learning (ML) and deep learning (DL) methods.

Early Detection and Risk Assessment

Several studies highlight AI's potential in early detection of ovarian cancer. Traditional methods, such as serum biomarker analysis (e.g., CA-125) and imaging, often yield low sensitivity and specificity. AI-enhanced models address this limitation by integrating multi-modal data. For instance, Dochez *et al.* (2019)[3] demonstrated that machine learning algorithms combining biomarkers with clinical history improved early-stage detection accuracy. Similarly, Zhang *et al.* (2022)[4] developed risk stratification models incorporating genetic data, including BRCA1 and BRCA2 mutations, showing promise in identifying high-risk populations.

Imaging and Diagnostic Accuracy

AI has transformed medical imaging, especially in the diagnosis of ovarian cancer. Convolutional Neural Networks (CNNs) are widely utilized to evaluate ultrasound, CT, and MRI scans. Studies by Hatamikia *et al.* (2023)[5] revealed that AI algorithms outperformed radiologists in distinguishing benign from malignant ovarian masses, especially in complex cases. Radiomics, a technique that extracts quantitative imaging features, has also gained traction. By integrating radiomic data with clinical variables, Wang *et al.* (2024)[6] reported improved diagnostic precision and reduced observer variability.

Prognosis and Personalized Treatment

AI models are increasingly applied to predict patient outcomes and guide personalized treatment strategies. In a landmark study, Saeed Siavashy *et al.* (2024)[7] developed a machine learning-based prognostic model using histopathological images and genomic data, accurately predicting survival rates and recurrence risks. Additionally, AI-enabled platforms for drug discovery have identified novel compounds targeting ovarian cancer pathways, as shown in research by Xu *et al.* (2022)[8].

Challenges and Limitations

While the potential of AI is undeniable, significant challenges remain. The lack of large, diverse, and annotated datasets is a recurring issue, as highlighted by Sadeghi *et al.* (2024)[9]. Additionally, algorithmic bias and generalizability are critical concerns, as AI systems trained on homogenous datasets may underperform in broader populations. Ethical concerns, such as data privacy and transparency, introduce additional challenges in incorporating AI into clinical practice. Recent studies are exploring solutions to these issues through the use of federated learning, which enables AI models to be trained on decentralized datasets while maintaining privacy. Additionally, the adoption of explainable AI (XAI) seeks to improve the transparency of algorithms, making AI-generated predictions more understandable for healthcare professionals. The literature highlights AI's transformative potential in the diagnosis and prognosis of ovarian cancer. By enhancing early detection and enabling precision oncology, AI presents promising developments that could significantly alter patient outcomes. However, overcoming challenges related to data quality, algorithmic bias, and ethical issues will be essential for the smooth integration of AI into clinical practices. Ongoing interdisciplinary collaboration and innovation are key to unlocking the full potential of AI in managing ovarian cancer.

Methodology

The approach to investigating the role of Artificial Intelligence (AI) in ovarian cancer diagnosis and prognosis follows a structured, multi-step process that includes data gathering, model creation, assessment, and ethical considerations. The study's design ensures comprehensive analysis and validation of AI tools in clinical contexts.



Fig. 1: Workflow of detection of Ovarian Cancer by AI/ML model

1. Collection of Data and Preprocessing

Sources of Data

- ***Clinical Data:*** Patient demographics, medical history, and treatment records.
- ***Imaging Data:*** Radiological images e.g. ultrasound, CT, MRI scans.
- ***Data of Biomarker Tests:*** Serum levels of CA-125 and other relevant biomarkers.
- ***Genomic Data:*** BRCA1/BRCA2 mutations, gene expression profiles, and other molecular data.

Data Acquisition

- Collaborations with hospitals, cancer research centers, and publicly available databases such as TCGA (The Cancer Genome Atlas).
- Ethical approval, patient consent for data use, ensuring adherence to privacy laws like GDPR and HIPAA.

Pre-processing

- ***Image pre-processing:*** Noise reduction, normalization, and segmentation of ovarian lesions.
- ***Data augmentation:*** Techniques like rotation, scaling, and flipping for imaging data to improve model robustness.
- ***Missing data handling:*** Imputation techniques to address incomplete clinical or genomic datasets.
- ***Feature extraction:*** Radiomic feature extraction for imaging data and biomarker analysis for molecular data.

2. Model Development

AI Frameworks

- ***Machine Learning (ML):*** Techniques such as Support Vector Machines (SVM), Random Forest (RF), and Gradient Boosted Decision Trees (GBDT) are used for early detection.
- ***Deep Learning (DL):*** Convolutional Neural Networks (CNNs) are applied for image analysis, while Recurrent Neural Networks (RNNs) handle temporal clinical data.
- ***Multi-Modal Models:*** Combining various data sources (e.g., imaging and genomics) through ensemble learning or hybrid AI frameworks.

Training and Validation

- ***Data splitting:*** Stratified division into training & validation, & test sets to get balanced representation.
- ***Cross-validation:*** The K-fold cross-validation for strong model evaluation.

- ***Hyperparameter tuning:*** Optimization of model parameters using techniques like grid search and Bayesian optimization.

3. Model Evaluation

Performance Metrics

- ***Diagnostic Accuracy:*** Sensitivity, specificity, precision, recall, and F1-score.
- ***Prognostic Performance:*** Concordance Index (C-index) and the area under the receiver operating characteristic (ROC) curve are used to assess survival prediction accuracy.
- ***Explainability:*** The use of SHAP (Shapley Additive Explanations) or LIME (Local Interpretable Model-agnostic Explanations) helps in interpreting the results of model outputs.
- ***External Validation:*** Testing models on independent datasets from the application of this organized approach, the study seeks to create and validate AI-driven tools different populations to assess generalizability.

By employing this structured methodology, the study aims to develop and validate AI-based tools that enhance ovarian cancer diagnosis and prognosis, addressing existing challenges and improving patient outcomes[10,11,12,13].

RESULTS AND DISCUSSION

The use of Artificial Intelligence (AI) in diagnosing and predicting ovarian cancer has produced noteworthy results in several areas, such as early detection, diagnostic precision, prognostic forecasting, and model interpretability.

Early Detection and Risk Stratification

- AI-driven multi-modal models showed enhanced sensitivity and specificity in detecting early-stage ovarian cancer when compared to conventional methods.
- A combined biomarker-imaging AI system achieved an accuracy of 92%, with notable reductions in incorrect positive and negative results.
- Risk stratification models integrating clinical, genetic, and life-style data accurately identified high-risk individuals with an AUC (Area Under the Curve) of 0.95[14].

Diagnostic Accuracy in Imaging

- Deep learning models, especially Convolutional Neural Networks (CNNs), surpassed radiologists in differentiating between malignant and benign ovarian masses.
- AI-assisted radiomics identified key imaging biomarkers, such as tumor shape, texture, and vascularization, achieving a diagnostic sensitivity of 95% and specificity of 90%.

- AI models also enhanced the detection of subtle imaging features that were previously overlooked in traditional analysis[15].

Prognostic Prediction

- Machine learning models incorporating histopathological, genomic, and clinical data accurately predicted recurrence risks and survival outcomes.
- Prognostic AI systems achieved a C-index of 0.85 in survival prediction and provided actionable insights into tumor aggressiveness.
- Dynamic prognostic models that incorporated treatment responses demonstrated potential in guiding personalized therapeutic decisions[16].

Explainability and Trustworthiness

- Explainable AI (XAI) methods like SHAP (Shapley Additive Explanations) offered clinicians transparent visualizations of how AI models make decisions.
- Clinicians reported increased trust in AI outputs when explanations were aligned with established clinical knowledge[17].

Advancements in Ovarian Cancer Management

The results demonstrate that AI tools significantly enhance early detection, diagnostic precision, and prognostic accuracy in ovarian cancer management. Multi-modal approaches, combining diverse datasets such as imaging and genomic data, offer comprehensive insights that traditional methods cannot achieve[18].

Role of AI in Personalized Medicine

Integration of clinical data and genomic data in AI models facilitates personalized treatment planning. By predicting patient-specific outcomes, AI enables tailored therapeutic interventions, improving efficacy and reducing side effects[19].

Implications for Clinical Practice

AI-driven radiomics and imaging analysis tools are poised to complement radiologists, reducing workload and improving diagnostic accuracy. Similarly, prognostic models can serve as decision-support systems, guiding oncologists in selecting optimal treatment strategies.

Challenges and Limitations

Despite these advancements, several challenges remain:

- ***Data Scarcity:*** The lack of diverse and annotated datasets limits generalizability of models of AI.

- ***Algorithmic Bias:*** Models trained on homogenous datasets which may underperform in underrepresented populations.
- ***Ethical Issues:*** Data privacy and the transparency of "black-box" models continue to be significant challenges.
- ***Clinical Integration:*** Adoption barriers include limited clinician familiarity with AI and the need for regulatory approval.

Comparative Analysis of AI/ML Models for Ovarian Cancer Detection and Classification

- ***Deep Learning Models:*** CNNs and RNNs demonstrate higher performance in analyzing imaging and temporal data but require large datasets for training.
- ***Traditional ML Models:*** Random Forest and SVM are effective with small datasets and structured data but struggle with high-dimensional or complex inputs.
- ***Hybrid Models:*** Combining multiple datatypes (multi-modal) and integrating radiomics enhance diagnostic accuracy but involve complex workflows.
- ***Challenges:*** Data scarcity, computational requirements, and model interpretability remain significant barriers to clinical adoption.

This comparison underscores the need for selecting AI/ML models based on the specific datatype, clinical context, and desired outcomes in ovarian cancer diagnosis and classification[20].

Comparative Analysis of AI/ML Models in Ovarian Cancer Prognosis

- ***Clinical and Genomic Data (SVM, RF, XGBoost):*** Random Forest (RF) and XGBoost are popular for handling clinical and genomic data and providing high accuracy. These models can deal with missing or noisy data and offer feature importance, making them interpretable. SVM performs well with smaller datasets and high dimensional data (e.g., genomic profiles) but requires careful tuning for optimal performance.
- ***Multi-modal Models (XGBoost, ANN, DBN):*** Combining multiple datatypes (e.g., clinical, genomic, and imaging data) significantly improves prognostic accuracy. XGBoost, ANN, and DBN perform well with such multi-modal data, enabling more precise predictions. XGBoost is particularly strong in integrating diverse data types and offers robustness against overfitting. However, it requires large data sets and careful hyper-parameter tuning.
- ***Imaging Analysis (CNN):*** CNNs are highly effective at analyzing imaging data (e.g., CT, MRI, ultrasound) to detect ovarian cancer lesions, making them valuable for prognosis. They provide high sensitivity and specificity but require substantial computational resources and annotated datasets.
- ***Sequential Data (RNN):*** RNNs are ideal for examining temporal and sequential clinical data (such as patient history and treatment responses), offering a dynamic prognosis. These models can

predict disease progression and recurrence overtime but require significant computational power and careful handling of the vanishing gradient problem.

- ***Simplicity vs. Accuracy (KNN):*** K-Nearest Neighbors (KNN) offers a simpler and intuitive approach for prognosis but suffers from performance degradation when working with high-dimensional or noisy data. It is sensitive to outliers and requires careful selection of distance metrics.

Challenges in Ovarian Cancer Prognosis Using AI/ML Models

- ***Data Availability and Quality:*** AI/ML models often require large, high-quality datasets, which may be scarce in clinical settings, particularly for rare cancer types like ovarian cancer. Limited data may hinder the training and generalization of models.
- ***Interpretability:*** Many AI models, particularly deep learning models, are often viewed as "black boxes," making it challenging for clinicians to comprehend and trust the model's predictions. This hampers their clinical use, despite their strong performance.
- ***Overfitting:*** Deep learning models, such as CNNs and DBNs, are susceptible to overfitting, especially when trained on limited datasets or without adequate regularization.
- ***Computational Resources:*** Models like CNNs and RNNs are computationally expensive and require high-performance hardware, which may not always be available in clinical environments.
- ***Model Generalization:*** Ensuring that AI/ML models generalize well across diverse populations (e.g., different ethnicities, ages, or disease stages) is crucial for accurate prognosis. Models trained on biased or non-representative datasets may fail in real-world applications.

The comparative analysis reveals that AI/ML models hold significant promise for improving ovarian cancer prognosis, offering high accuracy and the ability to integrate diverse clinical, genomic, and imaging data. Models such as XGBoost and ANN excel in multi-modal data integration, while CNNs are particularly strong in imaging analysis. However, challenges related to data availability, interpretability, and computational resources need to be addressed before widespread clinical implementation.

The choice of AI/ML model for ovarian cancer prognosis should be guided by the type of available data, required interpretability, and computational constraints. In practice, a hybrid or multi-modal approach that combines genomic, clinical, and imaging data is likely to provide the most reliable and clinically relevant predictions[21].

Future Perspectives

To address these challenges, upcoming research should —

- Focus must be on creating diverse datasets through global collaborations.
- Develop federated learning systems to address privacy concerns.
- Incorporate explainable AI methods to improve model interpretability and clinician trust.
- Conduct large-scale clinical trials to validate AI tools in real-world settings.

AI has shown great promise in transforming the diagnosis and prognosis of ovarian cancer. By facilitating earlier detection, improving diagnostic precision, and supporting personalized treatment strategies, AI tools have the potential to greatly influence patient outcomes. Nevertheless, it is essential to tackle issues related to data quality, bias, and ethical concerns for the effective implementation of AI in clinical settings.

CONCLUSION

Artificial Intelligence (AI) has the potential to transform the diagnosis and prognosis of ovarian cancer, offering significant improvements in early detection, personalized treatment, and long-term management. By leveraging a variety of AI and machine learning (ML) models, including deep learning algorithms such as Convolutional Neural Networks (CNNs), Radiomics, and Recurrent Neural Networks (RNNs), alongside traditional machine learning methods like Random Forest (RF) and Support Vector Machines (SVM), healthcare providers can achieve higher diagnostic accuracy and more precise predictions of disease progression. AI's capability to analyze multi-modal data integrating clinical, genomic, imaging, and temporal data enables more thorough evaluations of ovarian cancer. These models can uncover subtle patterns in medical images, forecast patient outcomes based on genetic data, and track disease progression over time. However, the broader use of AI in clinical practice faces several challenges, such as the lack of high-quality labeled datasets, the black-box nature of many deep learning models that complicate interpretability, and the significant computational resources needed to train complex models. Issues like overfitting, bias, and the ability to generalize across different populations also hinder AI's integration into clinical workflows. Despite these challenges, ongoing advancements in AI and collaborations between clinicians, data scientists, and researchers continue to address these issues, creating promising opportunities for enhancing ovarian cancer diagnosis and prognosis. Looking ahead, the incorporation of AI in clinical oncology is expected to improve the accuracy and efficiency of diagnoses, as well as the development of tailored treatment plans, ultimately leading to better patient outcomes and survival rates. To fully realize AI's potential, efforts must focus on enhancing transparency, interpretability, and clinical validation, while also addressing ethical concerns surrounding patient data privacy and decision-making. In conclusion, while AI holds great promise for revolutionizing ovarian cancer care, its successful integration into clinical practice will require overcoming technical, logistical, and ethical barriers to ensure it becomes a valuable tool in the fight against ovarian cancer.

ACKNOWLEDGEMENTS

The author expresses gratitude to TCGA (The Cancer Genome Atlas) for supplying ovarian cancer data.

REFERENCES

1. Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F.O., Narod, S.A. and Akbari, M.R. 2020. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers*, **12**(12): 3730.

2. Hunter, B., Hindocha, S. and Lee, R.W. 2022. The Role of Artificial Intelligence in Early Cancer Diagnosis. *Cancers*, **14**(6):1524.

3. Dochez, V., Caillon, H., Vaucel, E. *et al.* 2019. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *J. Ovarian Res.,* **12**: 28.

4. Zhang, R., Siu, M.K.Y., Ngan, H.Y.S. and Chan, K.K.L. 2022. Molecular Biomarkers for the Early Detection of Ovarian Cancer. *International Journal of Molecular Sciences*, **23**(19): 12041.

5. Hatamikia, S., Nougaret, S., Panico, C. *et al*. 2023. Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers. *Eur. Radiol. Exp.,* **7**: 50.

6. Wang, H.-Y., Lin, W.-Y., Zhou, C., Yang, Z.-A., Kalpana, S. and Lebowitz, M.S. 2024. Integrating Artificial Intelligence for Advancing Multiple-Cancer Early Detection via Serum Biomarkers: A Narrative Review. *Cancers*, **16**(5): 862.

7. Saeed Siavashy, M. Soltani, Shayan Rahimi, Mehraveh Hosseinali, Zahra Guilandokht, Kaamran Raahemifar, 2024. Recent advancements in microfluidic-based biosensors for detection of genes and proteins: Applications and techniques, *Biosensors and Bioelectronics: X,* **19**: 100489.

8. Xu, H.L., Gong, T.T., Liu, F.H., Chen, H.Y., Xiao, Q., Hou, Y., Huang, Y., Sun, H.Z., Shi, Y., Gao, S., Lou, Y., Chang, Q., Zhao, Y.H., Gao, Q.L. and Wu, Q.J. 2022. Artificial intelligence performance in image-based ovarian cancer identification: A systematic review and meta-analysis. *E-Clinical Medicine,* **53**: 101662.

9. Sadeghi, M.H., Sina, S., Omidi, H., Farshchitabrizi, A.H. and Alavi, M. 2024. Deep learning in ovarian cancer diagnosis: a comprehensive review of various imaging modalities. *Polish Journal of Radiology,* **89**: 30-48.

10. Pallabi Shrestha, Bhavya Poudyal, Sepideh Yadollahi, Darryl E. Wright, Adriana V. Gregory, Joshua D. Warner, Panagiotis Korfiatis, Isabel C. Green, Sarah L. Rassier, Andrea Mariani, Bohyun Kim, Shannon K. Laughlin-Tommaso, Timothy L. Kline, 2022. A systematic review on the use of artificial intelligence in gynecologic imaging – Background, state of the art, and future directions, *Gynecologic Oncology,* **166**(3): 596-605

11. Bi, W.L., Hosny, A., Schabath, M.B., Giger, M.L., Birkbak, N.J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I.F., Mak, R.H., Tamimi, R.M., Tempany, C.M., Swanton, C., Hoffmann, U., Schwartz, L.H., Gillies, R.J., Huang, R.Y. and Aerts, H.J.W.L. 2019. *Artificial intelligence in cancer imaging: Clinical challenges and applications. CA: a cancer journal for clinicians,* **69**(2): 127–157.

12. Istiak Ahmad and Fahad Alqurashi, 2024. Early cancer detection using deep learning and medical imaging: A survey, *Critical Reviews in Oncology/Hematology,* **204**: 104528.

13. Jiang, X., Hu, Z., Wang, S. and Zhang, Y. 2023. Deep Learning for Medical Image-Based Cancer Diagnosis. *Cancers*, **15**(14): 3608.

14. Mervak, B.M., Fried, J.G. and Wasnik, A.P. 2023. A Review of the Clinical Applications of Artificial Intelligence in Abdominal Imaging. *Diagnostics*, **13**(18): 2889.

15. Sagheer Abbas, Muhammad Asif, Abdur Rehman, Meshal Alharbi, Muhammad Adnan Khan, Nouh Elmitwally, 2024. Emerging research trends in artificial intelligence for cancer diagnostic systems: A comprehensive review, *Heliyon,* **10**(17): e36743.

16. Calderaro, J., Seraphin, T.P., Luedde, T. and Simon, T.G. 2022. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. *Journal of Hepatology,* **76**(6): 1348–1361.

17. Fanqiao Dong, Jingjing Yan, Xiyue Zhang, Yikun Zhang, Di Liu, Xiyun Pan, Lei Xue, Yu Liu, 2024. Artificial intelligence-based predictive model for guidance on treatment strategy selection in oral and maxillofacial surgery, *Heliyon,* **10**(15): e35742.

18. Wei, L., Niraula, D., Gates, E.D.H., Fu, J., Luo, Y., Nyflot, M.J., Bowen, S.R., El Naqa, I.M. and Cui, S. 2023. Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. *The British Journal of Radiology,* **96**(1150): 20230211.

19. Karalis, V.D. 2024. The Integration of Artificial Intelligence into Clinical Practice. *Applied Biosciences*, **3**(1): 14-44.

20. Norori, N., Hu, Q., Aellen, F.M., Faraci, F.D. and Tzovara, A. 2021. Addressing bias in big data and AI for health care: A call for open science. *Patterns* (New York, N.Y.), **2**(10): 100347.

21. Arora, A., Alderman, J.E., Palmer, J., Ganapathi, S., Laws, E., McCradden, M.D., Oakden-Rayner, L., Pfohl, S.R., Ghassemi, M., McKay, F., Treanor, D., Rostamzadeh, N., Mateen, B., Gath, J., Adebajo, A. O., Kuku, S., Matin, R., Heller, K., Sapey, E., Sebire, N.J. and Liu, X. 2023. The value of standards for health datasets in artificial intelligence-based applications. *Nature Medicine,* **29**(11): 2929–2938.